Premium
Effect of Almonds on Glucoregulation and CVD Risk Factors in Patients with Type 2 Diabetes
Author(s) -
Chen CM,
Liu JF,
Huang CL,
Hsirh AT,
Weng SF,
Li SC,
Chao TY,
Chen CY
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.912.3
Subject(s) - glycemic , postprandial , medicine , type 2 diabetes , placebo , diabetes mellitus , oxidative stress , endocrinology , alternative medicine , pathology
Our previous 4‐wk study showed that almond consumption improved glycemic control and cholesterols and ameliorated oxidative stress and inflammation in Chinese patients with type 2 diabetes (T2D). This randomized, cross‐over, placebo controlled feeding trial further examined health benefits of the consumption of ~60 g/d almonds (Alm) in control diet (Con) for 3 mo on glucoregulation and CVD risk factors, as compared to Con. Among the 33 patients who completed the trial, the diets did not have a different impact on cholesterols, glycemic control, inflammation, endothelial function, and oxidative stress. Of the 33 patients, 21 complied with the treatments based on the data of 12% increase in plasma α‐tocopherol (P = .02). Among 17 of these 21 patients with the baseline HbA1c 蠄8, Alm decreased post‐interventional fasting HbA1c and glucose by 4 & 11% as compared to Con, respectively (P = .03 & .001). Similarly, in a glucose tolerance test, Alm lessened postprandial glucose increase at 30, 60, and 90 min and area under the glucose curve by 7, 7, 6, and 6% compared to Con, respectively (P = .03, .04, .05 & .01). HOMA‐IR tended to be reduced by 21% by Alm compared to Con (P = .1), and serum Mg was increased by 5% (P = .03). Blood cholesterols were not decreased by Alm, probably due to well controlled TC and LDL‐C. In conclusion, almond consumption is beneficial for glycemic control in patients with T2D.